Stockysis — AI-Powered Stock News & Sentiment Analysis

HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $6

Benzinga Newsdesk www.benzinga.com Neutral 71.3%

Neg 0% Neu 71.3% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $10 to $6.

Comments

No comments yet. Be the first!